4//SEC Filing
Danilkovitch Alla 4
Accession 0001104659-19-021850
CIK 0001360886other
Filed
Apr 16, 8:00 PM ET
Accepted
Apr 17, 9:35 AM ET
Size
29.3 KB
Accession
0001104659-19-021850
Insider Transaction Report
Form 4
Danilkovitch Alla
Chief Scientific Officer
Transactions
- Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−8,000→ 0 totalExercise: $7.74Exp: 2020-03-12→ Common Stock (8,000 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−6,000→ 0 totalExercise: $5.08Exp: 2022-03-23→ Common Stock (6,000 underlying) - Disposition to Issuer
Common Stock
2019-04-17$19.00/sh−9,375$178,125→ 0 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2019-04-17−17,356→ 0 totalExercise: $18.40Exp: 2025-03-06→ Common Stock (17,356 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−9,000→ 0 totalExercise: $7.13Exp: 2021-02-14→ Common Stock (9,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2019-04-17−24,997→ 0 totalExercise: $6.80Exp: 2027-07-19→ Common Stock (24,997 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−10,000→ 0 totalExercise: $7.73Exp: 2023-02-12→ Common Stock (10,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2019-04-17−1,436→ 0 totalExercise: $14.00Exp: 2024-05-06→ Common Stock (1,436 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−7,644→ 0 totalExercise: $18.40Exp: 2025-03-06→ Common Stock (7,644 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−25,003→ 0 totalExercise: $6.80Exp: 2027-07-19→ Common Stock (25,003 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−5,000→ 0 totalExercise: $6.46Exp: 2020-05-27→ Common Stock (5,000 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2019-04-17−18,564→ 0 totalExercise: $14.00Exp: 2024-05-06→ Common Stock (18,564 underlying)
Footnotes (2)
- [F1]On March 12, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Smith & Nephew Consolidated, Inc., a Delaware corporation ("Parent"), Papyrus Acquisition Corp., a Maryland corporation and a direct subsidiary of Parent ("Purchaser") and Smith & Nephew plc, an English public limited company. Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired at a purchase price of $19.00 per share (the "Offer Price") in cash.
- [F2]Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal to the excess, if any, of (A) the Offer Price over (B) the exercise price per share of such stock option, multiplied by the number of shares of Common Stock subject to such option.
Documents
Issuer
OSIRIS THERAPEUTICS, INC.
CIK 0001360886
Entity typeother
Related Parties
1- filerCIK 0001636236
Filing Metadata
- Form type
- 4
- Filed
- Apr 16, 8:00 PM ET
- Accepted
- Apr 17, 9:35 AM ET
- Size
- 29.3 KB